What was the challenge faced by the pharmaceutical company?

The organization faced challenges including protecting proprietary R&D data and formulae, managing digital risk across geographically dispersed manufacturing units, complying with pharmaceutical data protection regulations like US FDA 21 CFR Part 11, EU GMP Annex 11, and India's CDSCO norms, securing collaboration platforms, detecting threats to lab automation systems, and minimizing attacker dwell time.

What results were achieved with Invinsense?

The company achieved 3.8X improvement in early stage threat detection across R&D environments, 73% of exposed assets patched in first 60 days, 92% compliance alignment with global pharmaceutical data standards, and 5.4X increase in detection accuracy via deception assets.

Securing Innovation at Scale

The Challenge

Operating at the intersection of science and technology, the organization faced distinct cybersecurity and regulatory challenges:

Protecting proprietary R&D data and formulae stored across cloud-based lab systems and internal data lakes
Managing digital risk across geographically dispersed manufacturing units
Complying with pharmaceutical data protection regulations like US FDA 21 CFR Part 11, EU GMP Annex 11, and India’s CDSCO norms
Securing collaboration platforms used by scientists, regulatory affairs teams, and manufacturing operators
Detecting threats that could compromise lab automation systems and IP pipelines
- Minimizing dwell time of attackers in sensitive environments

The Invinsense Solution

The company adopted Invinsense to proactively detect, validate, and respond to threats across R&D, production, and global compliance systems — while embedding security in their innovation lifecycle.

Invinsense XDR: Visibility Across Science, Systems, and Supply Chain

Invinsense XDR delivered real-time monitoring and response across the customer’s hybrid environment — including cloud-hosted lab management systems, smart manufacturing units, ERP, and remote R&D setups.

Key Results:

Reduced mean time to detect (MTTD) from 18.5 mins to 4.9 mins
Achieved 86% visibility into devices used in manufacturing automation
3.8x increase in early detection of threats in IP repositories
Correlated security events with supply chain workflows, improving alert triage accuracy by 61%

Invinsense OXDR: CTEM Tailored to R&D and Compliance Risk

The organization initiated a CTEM (Continuous Threat Exposure Management) program to continuously assess and mitigate risks across research, production, and regulatory platforms.

Scoping	Mapped 2,700+ assets across lab networks, regulatory data portals, IoT systems, and cloud workloads Identified 112 shadow applications used for file-sharing by research teams
Discovery	Discovered 186 high-risk vulnerabilities in legacy quality assurance modules and outdated production controllers Detected API keys exposed in Git-based collaborative coding environments
Prioritization	Focused on vulnerabilities impacting data integrity in FDA-regulated lab data Emulated potential lateral movement from collaboration portals to regulatory document repositories
Validation	Simulated attacker path from phishing-infected R&D devices to IP data stores Tested ransomware impact on formulation database backups and validated recovery playbooks
Mobilization	73% of exposed assets were patched within the first 60 days Security engineering team deployed 18 custom remediation workflows integrated into change control systems

Invinsense XDR+: Deceptive Defense for Intellectual Property Zones

Deception environments were crafted to mimic real IP repositories, lab processing modules, and legacy manufacturing PLCs, drawing in and studying adversary behavior.

Results:

Detected 3 targeted IP reconnaissance attempts via decoy repositories
Increased attacker interaction time by 5.4x
Enabled faster attribution of suspicious activity to insider threat vectors
Early alerting from deception helped preempt 2 credential compromise campaigns

Invinsense GSOS: Global Pharma Compliance Made Traceable

GSOS was used to align cybersecurity controls to multiple regulatory mandates — including:

21 CFR Part 11 (electronic records and signatures)
EU GMP Annex 11 (computerized systems)
India CDSCO digital safety requirements
GAMP 5 guidelines for system validation

CTEM Outcome

Time to validate high-risk exposures reduced by 62%
Mean attacker dwell time dropped from 11 days to 3
4.1x improvement in patch validation success rate across distributed units

Compliance Outcomes

92% alignment with targeted pharma regulatory controls
Reduced time to generate audit documentation by 78%
Enabled 100% traceability of system changes and access logs
Dashboards simplified board-level oversight and internal audit workflows

Executive Quote

“In our industry, data integrity is life-critical. Invinsense allowed us to protect what matters most — from molecule to market — with clarity, agility, and complete oversight.”

Quantifiable Impact

Category	Improvement
Threat Detection Time	from 18.5 to 4.9 mins
IP Zone Visibility	3.8x
CTEM Risk Validation Speed	62%
Compliance Alignment (Pharma-specific)	92%
Deceptive Defense Engagement	5.4x attacker interaction time
Audit Prep Efficiency	78%

Conclusion

For life sciences companies driving innovation and operating under strict global regulations, cybersecurity isn’t a checkbox — it’s a catalyst. By integrating Invinsense across threat detection, exposure validation, deceptive defense, and compliance, this pharmaceutical leader now advances science with digital trust at its core.